EUVIMEDEUVIMED entdecken
Crossref

PPARγ agonist inhibits c‐Myc‐mediated colorectal cancer tumor immune escape

Liuqian Xu, Suning Che, Huiqing Chen, Qian Liu, Juanjuan Shi, Jianhua Jin, Yongzhong Hou iD

Journal of Cellular Biochemistry · 2023

DOI: 10.1002/jcb.30437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2023. Verfasst von Liuqian Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Wujin Hospital, Jiangsu University, Changzhou, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Pioglitazone, Thiazolidinediones. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a master transcription factor, c‐Myc plays an important role in promoting tumor immune escape. In addition, PPARγ (peroxisome proliferator‐activated receptor γ) regulates cell metabolism, inflammation, and tumor progression, while the effect of PPARγ on c‐Myc‐mediated tumor immune escape is still unclear. Here we found that cells treated with PPARγ agonist pioglitazone (PIOG) reduced c‐Myc protein expression in a PPARγ‐dependent manner. qPCR analysis showed that PIOG had no significant effect on c‐Myc gene levels. Further analysis showed that PIOG decreased c‐Myc protein half‐life. Moreover, PIOG increased the binding of c‐Myc to PPARγ, and induced c‐Myc ubiquitination and degradation. Importantly, c‐Myc increased PD‐L1 and CD47 immune checkpoint protein expression and promoted tumor immune escape, while PIOG inhibited this event. These findings suggest that PPARγ agonist inhibited c‐Myc‐mediated tumor immune escape by inducing its ubiquitination and degradation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsPioglitazoneThiazolidinedionesHumansGene Expression RegulationPPAR gammaTumor EscapeProto-Oncogene Proteins c-myc

Stichwörter der Autor:innen

PPARγ agonistc-Mycdegradationtumor suppressionubiquitination

Substanzen

PioglitazonePPAR gammaThiazolidinedionesProto-Oncogene Proteins c-myc

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Wujin Hospital, Jiangsu University, Changzhou, Jiangsu, People's Republic of China.
  • School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.
  • Department of Oncology, Wujin Clinical College of Xuzhou Medical University, Changzhou, Jiangsu, People's Republic of China.

ORCID-Profile: Yongzhong Hou

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xu, L., Che, S., Chen, H., Liu, Q., Shi, J., Jin, J., & Hou, Y. (2023). PPARγ agonist inhibits c‐Myc‐mediated colorectal cancer tumor immune escape. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.30437

Vancouver

Xu L, Che S, Chen H, Liu Q, Shi J, Jin J, et al. PPARγ agonist inhibits c‐Myc‐mediated colorectal cancer tumor immune escape. Journal of Cellular Biochemistry. 2023. doi:10.1002/jcb.30437

BibTeX
@article{Xu2023,
  author = {Xu, Liuqian and Che, Suning and Chen, Huiqing and Liu, Qian and Shi, Juanjuan and Jin, Jianhua and Hou, Yongzhong},
  title = {PPARγ agonist inhibits c‐Myc‐mediated colorectal cancer tumor immune escape},
  journal = {Journal of Cellular Biochemistry},
  year = {2023},
  doi = {10.1002/jcb.30437}
}
Kostenlos starten →